AR068825A1 - Usos terapeuticos de antagonistas del receptor andrenergico alfa-1 - Google Patents

Usos terapeuticos de antagonistas del receptor andrenergico alfa-1

Info

Publication number
AR068825A1
AR068825A1 ARP080104131A ARP080104131A AR068825A1 AR 068825 A1 AR068825 A1 AR 068825A1 AR P080104131 A ARP080104131 A AR P080104131A AR P080104131 A ARP080104131 A AR P080104131A AR 068825 A1 AR068825 A1 AR 068825A1
Authority
AR
Argentina
Prior art keywords
andrenergic
alfa
antagonists
receiver
therapeutic uses
Prior art date
Application number
ARP080104131A
Other languages
English (en)
Spanish (es)
Inventor
Pierangelo Geppetti
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR068825A1 publication Critical patent/AR068825A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080104131A 2007-09-26 2008-09-24 Usos terapeuticos de antagonistas del receptor andrenergico alfa-1 AR068825A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97532407P 2007-09-26 2007-09-26
EP07291148A EP2042179A1 (de) 2007-09-26 2007-09-26 Neue therapeutische Verwendung adrenerger alpha-1-Rezeptorantagonisten

Publications (1)

Publication Number Publication Date
AR068825A1 true AR068825A1 (es) 2009-12-09

Family

ID=38754714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104131A AR068825A1 (es) 2007-09-26 2008-09-24 Usos terapeuticos de antagonistas del receptor andrenergico alfa-1

Country Status (15)

Country Link
US (1) US8492396B2 (de)
EP (2) EP2042179A1 (de)
JP (1) JP5478495B2 (de)
AR (1) AR068825A1 (de)
AT (1) ATE524185T1 (de)
CY (1) CY1112203T1 (de)
DK (1) DK2203170T3 (de)
ES (1) ES2373354T3 (de)
HR (1) HRP20110919T1 (de)
ME (1) ME01259B (de)
PL (1) PL2203170T3 (de)
PT (1) PT2203170E (de)
RS (1) RS52069B (de)
SI (1) SI2203170T1 (de)
WO (1) WO2009040671A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110933933B (zh) * 2018-07-18 2022-12-27 温州医科大学 一种治疗近视的方法及制备药物的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
WO1999002215A1 (en) * 1997-07-10 1999-01-21 Therakos, Inc. Treatment of inflammatory disorders of the bowel and urinary bladder
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002062389A1 (en) * 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
WO2004017960A1 (en) * 2002-08-14 2004-03-04 Janssen Pharmaceutica N.V. Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
MXPA05013905A (es) * 2003-07-02 2006-02-24 Hoffmann La Roche Compuestos de quinazolinona sustituidos por arilamina.
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

Also Published As

Publication number Publication date
SI2203170T1 (sl) 2012-01-31
ME01259B (me) 2013-06-20
WO2009040671A4 (en) 2009-05-28
EP2042179A1 (de) 2009-04-01
US20110009436A1 (en) 2011-01-13
JP2010540511A (ja) 2010-12-24
CY1112203T1 (el) 2015-12-09
WO2009040671A1 (en) 2009-04-02
PT2203170E (pt) 2011-12-27
EP2203170B1 (de) 2011-09-14
DK2203170T3 (da) 2012-01-16
HRP20110919T1 (hr) 2012-01-31
JP5478495B2 (ja) 2014-04-23
ATE524185T1 (de) 2011-09-15
RS52069B (sr) 2012-06-30
EP2203170A1 (de) 2010-07-07
ES2373354T3 (es) 2012-02-02
US8492396B2 (en) 2013-07-23
PL2203170T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CL2014003331A1 (es) Formas cristalinas de un modulador de receptor de androgeno
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
CL2016001895A1 (es) Compuestos
BR112012032282A2 (pt) administração transdérmica de memantina
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
CL2007000781A1 (es) Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
WO2011116161A3 (en) Arylsulfonamide ccr3 antagonists
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008003362A1 (es) Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Legal Events

Date Code Title Description
FB Suspension of granting procedure